China NMPA Drug Inspection - Sichuan Lesheng Pharmaceutical Co., Ltd. - Myrrh (vinegar myrrh)

On December 1, 2020, the Yunnan Provincial Drug Administration, under the National Medical Products Administration (NMPA), released its second official announcement regarding substandard drug quality for the year. This document serves as a public disclosure following province-wide sampling inspections aimed at strengthening medication safety. The report identifies several pharmaceutical manufacturers found in violation of safety and quality standards, including Henan Tianzhi Pharmaceutical Co., Ltd., Yunnan New Century Chinese Herbal Pieces Co., Ltd., and Sichuan Lesheng Pharmaceutical Co., Ltd., among others. Major violations identified during the inspections included the presence of visible foreign matter in Ozagrel Sodium Injections, excessive sulfur dioxide levels in Kudzu root, and failures in microscopic identification and content potency for various herbal products. Other issues noted were high total ash content and discrepancies in thin-layer chromatography results. These inspections were conducted under the regulatory framework of the Chinese Pharmacopoeia (2015 Edition) and specific state-level drug standards. The administration published these findings to alert the public and healthcare providers about non-compliant batches. While the announcement primarily serves as a transparency mechanism, it implies that regulatory departments will continue to supervise these entities to ensure corrective actions are taken to rectify manufacturing defects and prevent substandard products from reaching consumers.